The PIONEER trial programme showed that, after 52 weeks, the novel oral glucagon-like peptide-1 (GLP-1) analogue semaglutide 14 mg was associated with significantly greater reductions in glycated haemoglobin (HbA1c) versus a sodium-glucose cotransporter-2 inhibitor (empagliflozin 25 mg), dipeptidyl peptidase-4 (sitagliptin 100 mg) and an injectable GLP-1 (liraglutide 1.8 mg). aim of present analysis to assess long-term cost-effectiveness each these comparators UK setting.Analyses were...

Glucagon-like peptide-1 (GLP-1) receptor agonists are appealing as glucose-lowering therapy for individuals with type 2 diabetes mellitus (T2DM) they also reduce body weight and associated low rates of hypoglycaemia. This analysis assessed the long-term cost-effectiveness semaglutide 0.5 1 mg vs dulaglutide 1.5 (two once-weekly GLP-1 agonists) from a UK healthcare payer perspective, based on head-to-head SUSTAIN 7 trial, to inform decision making.Long-term outcomes were projected using IQVIA...

Objective Choosing therapies for type 2 diabetes that are both effective and cost-effective is vital as healthcare systems worldwide aim to maximize health of the population. The present analysis assessed cost-effectiveness once-weekly semaglutide (a novel glucagon-like peptide-1 (GLP-1) receptor agonist) versus insulin glargine U100 (the most commonly used basal insulin) dulaglutide (an alternative GLP-1 agonist), from a societal perspective in Netherlands. Research design methods IQVIA...

Aims: The efficacy and safety of oral semaglutide, the first glucagon-like peptide-1 (GLP-1) receptor agonist developed for administration treatment type 2 diabetes, was evaluated in PIONEER clinical trial program, a recently published network meta-analysis allowed comparison with further injectable GLP-1 agonists. present study aimed to assess short-term cost- effectiveness semaglutide 14 mg versus subcutaneous once-weekly dulaglutide 1.5 mg, exenatide twice-daily 10 µg, once-daily...

Once-weekly semaglutide is a novel glucagon-like peptide-1 (GLP-1) analog for the treatment of type 2 diabetes (T2D) that has been associated with greater reductions in glycated hemoglobin (HbA1c) and body weight versus GLP-1 receptor agonists dulaglutide, exenatide extended-release (ER), liraglutide lixisenatide SUSTAIN trial program network meta-analysis (NMA). The aim present study was to assess long-term cost-effectiveness all available Denmark, using clinically orientated approach....

Swedish National Diabetes Registry data show a correlation of improved glycemic control in people with type 1 diabetes (T1D) increased use technologies over the past 25 years. However, novel are often associated high initial outlay. The aim present study was to evaluate long-term cost-effectiveness advanced hybrid closed-loop (AHCL) MiniMed 780G system versus intermittently scanned continuous glucose monitoring (isCGM) plus self-injection multiple daily insulin (MDI) or subcutaneous infusion...

Glucagon-like peptide-1 (GLP-1) receptor agonists represent efficacious therapies for treating type 2 diabetes. Oral semaglutide is the only orally administered GLP-1 agonist currently available and has been associated with reductions in glycated hemoglobin body weight versus once-daily injectable liraglutide after 52 weeks PIONEER 4 clinical trial. As lower-cost formulations have recently developed, present analysis evaluated long-term cost-effectiveness of oral 14 mg 1.8 at lower...

Glucagon-like peptide-1 (GLP-1) receptor agonists represent highly efficacious treatment options for type 2 diabetes. Liraglutide was amongst the first authorised use in 2010, but once-weekly semaglutide represents most GLP-1 analogue currently available The aim of present analysis therefore to evaluate long-term cost-effectiveness 1 mg versus liraglutide 1.8 with a lowered acquisition cost UK, as potentially lower formulations may soon be developed. Outcomes were projected over patients’...

Oral semaglutide is the first orally administered glucagon-like peptide-1 receptor agonist for treatment of type 2 diabetes, and has been evaluated in PIONEER clinical trial program. These trials assessed proportions patients achieving single composite endpoints, encompassing glycemic control [defined terms glycated hemoglobin (HbA1c)], weight loss, hypoglycemia. The present study cost with oral versus empagliflozin, sitagliptin, liraglutide US. Four endpoints were evaluated: (1) HbA1c ≤...

Once-weekly semaglutide 1 mg is a novel glucagon-like peptide-1 receptor agonist (GLP-1 RA) for the treatment of type 2 diabetes that has demonstrated significantly greater reductions in glycated haemoglobin (HbA1c) and body weight than GLP-1 RA once-daily liraglutide 1.2 SUSTAIN 10 trial. The present analysis aimed to evaluate long-term cost-effectiveness once-weekly versus from UK healthcare payer perspective. Long-term outcomes were projected using IQVIA CORE Diabetes Model (version 9.0),...

Aims: Controlling costs while maximizing healthcare gains is the predominant challenge for providers, and therefore cost-effectiveness analysis playing an ever-increasing role in decision making. The aim of present was to assess long-term subcutaneous once-weekly semaglutide (0.5 mg 1 mg) versus empagliflozin (10 25 Spanish setting treatment patients with type 2 diabetes (T2D) inadequate glycemic control on oral anti-hyperglycemic medications.Material methods: IQVIA CORE Diabetes Model used...

AimsTo assess the long-term cost-effectiveness of novel glucagon-like peptide-1 (GLP-1) analog oral semaglutide versus sodium-glucose cotransporter-2 inhibitor empagliflozin, dipeptidyl peptidase-4 sitagliptin and injectable GLP-1 liraglutide in Netherlands, based on results PIONEER clinical trials.MethodsOutcomes were projected over patient lifetimes using IQVIA CORE Diabetes Model. Clinical data derived from 2, 3 4. Patients assumed to receive initial treatments until glycated hemoglobin...

To evaluate the economic and clinical burden associated with poor glycaemic control in Sweden, people type 2 diabetes (T2D) initiating first-line glucose-lowering therapy.Population data were obtained from Swedish national registers. Immediate was compared delays achieving of 1 3 years, outcomes projected over 3, 10 50 years validated IQVIA CORE Diabetes Model. Glycaemic defined as glycated haemoglobin (HbA1c) targets 52, 48 42 mmol/mol, recommended guidelines, according to age disease...

Once-weekly semaglutide is a novel glucagon-like peptide-1 (GLP-1) analogue for the treatment of type 2 diabetes that was associated with greater reductions in glycated hemoglobin (HbA1c) and body mass index (BMI) versus once-daily GLP-1 liraglutide recent network meta-analysis (NMA). The aim present study to assess long-term cost-effectiveness once-weekly 1 mg 1.2 Estonia. Outcomes were projected over patient lifetimes using IQVIA CORE Diabetes Model (version 9.0), baseline cohort...

Glucagon-like peptide-1 (GLP-1) receptor agonists represent a class of treatments for type 2 diabetes that offer multifactorial benefits, including glycemic control, weight loss and low hypoglycemia risk. Once-weekly semaglutide is novel GLP-1 analog has been associated with improved control reduced body mass index (BMI) versus once-weekly agonist dulaglutide in SUSTAIN 7, which reimbursed patients BMI > 35 kg/m2 Slovakia. The aim the present study was to evaluate long-term...

Healthcare systems aim to maximize the health of population, but must work within constrained budgets. Therefore, choosing therapies that are both effective and cost-effective is paramount. The present analysis assessed cost-effectiveness once-weekly semaglutide 0.5 mg 1 versus dulaglutide 1.5 once daily sitagliptin 100 for treatment patients with type 2 diabetes inadequate glycemic control on oral anti-hyperglycemic medications over patient lifetimes from a healthcare payer perspective in...

Oral semaglutide is a novel glucagon-like peptide-1 (GLP-1) analog that has been associated with improvements in glycated hemoglobin (HbA1c) and body weight versus sodium-glucose cotransporter-2 inhibitor empagliflozin injectable GLP-1 receptor agonist dulaglutide the PIONEER 2 clinical trial recent network meta-analysis (NMA), respectively. The aim of present study was to evaluate long-term cost-effectiveness oral 14 mg 25 1.5 for treatment type diabetes from healthcare payer perspective...

Aim To evaluate the cost‐effectiveness of IDegLira versus basal‐bolus therapy (BBT) with insulin glargine U100 plus up to 4 times daily aspart for management type 2 diabetes in UK. Methods A Microsoft Excel model was used cost‐utility BBT over a 1‐year time horizon. Clinical input data were taken from treat‐to‐target DUAL VII trial, conducted patients unable achieve adequate glycaemic control (HbA1c <7.0%) basal insulin, associated lower rates hypoglycaemia and reduced body mass index...

We have recently reported a new and rapid assay to measure plasma holotranscobalamin II (holo TC II) as means of exploring vitamin B12 status. In order further evaluate the significance holoTC in determining tissue cobalamin, we chosen red blood cell-vitamin (RBC-B12) content studied relationship between RBC-B12 levels. Plasma concentrations were concomitantly assayed 20 hematologically normal controls cancer patients. our groups controls, mean value was determined 241 +/- 51 pg/ml packed...

Background and aims The ReFLeCT study demonstrated that switching to insulin degludec from other basal insulins was associated with reductions in glycated hemoglobin hypoglycemic events type 1 (T1D) 2 diabetes (T2D), doses T1D. aim of the present analysis assess short- long-term cost-effectiveness Sweden.Methods Short-term outcomes were evaluated over year a Microsoft Excel model, while projected patient lifetimes using IQVIA CORE Diabetes Model. Cohort characteristics treatment effects...

Once-weekly semaglutide has been associated with greater reductions in glycated hemoglobin (HbA1c) and body weight than sitagliptin dulaglutide the SUSTAIN 2 7 clinical trials, respectively. These trials also assessed proportions of patients achieving treatment targets capturing glycemic control avoidance hypoglycemia gain. This study cost bringing type diabetes to three clinically relevant endpoints versus Spain. The HbA1c < 7.0%, 7.0% without gain, a ≥ 1.0% reduction 5.0% loss were taken...

To evaluate the long-term cost-effectiveness of once-weekly semaglutide 1 mg versus insulin aspart in UK.Long-term outcomes were projected over patients' lifetimes using IQVIA CORE Diabetes Model (vers 9.0). SUSTAIN 11 was used to inform baseline cohort characteristics and treatment effects. Patients modelled receive plus basal for 3 years before intensifying basal-bolus insulin, compared with arm. Costs accounted from a healthcare payer perspective UK, expressed 2021 pounds sterling...

Once-weekly semaglutide and dulaglutide represent two highly efficacious treatment options for type 2 diabetes. A recent indirect comparison (ITC) has associated 1 mg with similar greater improvements in glycated haemoglobin (HbA1c) body weight, respectively, vs. 3 4.5 mg. The present study aimed to evaluate the long-term cost-effectiveness of UK.The IQVIA CORE Diabetes Model (v9.0) was used project outcomes over patients' lifetimes. Baseline cohort characteristics were sourced from SUSTAIN...

Effective glycemic control can reduce the risk of complications and their related costs in patients with type 2 diabetes (T2D). Many fail to reach hemoglobin A1c (HbA1c) ≤ 6.5% or < 7.0%, often due adverse effects treatment, such as hypoglycemia weight gain. Glycemic targets should be individualized consider multiple factors, including events patient's characteristics comorbid conditions.